N-Benzyl-malonsaeure-diamid | 90918-19-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Benzyl-malonsaeure-diamid
• 英文别名: benzyl malonamide；N'-benzylpropanediamide
• CAS: 90918-19-7
• 化学式: C₁₀H₁₂N₂O₂
• 分子量: 192.217
• InChiKey: YGAPUPZYQQFWFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  500.7±43.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Benzyl-malonsaeure-diamid 在 苯磺酰基叠氮化物 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 27.0h， 生成 Sodium; 3-benzyl-5-carbamoyl-3H-[1,2,3]triazol-4-olate 、 Sodium; 5-benzylcarbamoyl-3H-[1,2,3]triazol-4-olate
  参考文献：
  名称：

  Synthesis and study of the cyclization pathways and reactivities of ?-diazoimidolates

  摘要：

  DOI：

  10.1007/bf00471750

文献信息

• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：——

  公开号：US20010051633A1

  公开（公告）日：2001-12-13

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑，精神病，惊厥，氨基糖苷类抗生素引起的听力损失，偏头痛，慢性疼痛，帕金森病，青光眼，巨细胞病毒性视网膜炎，尿失禁，阿片类耐受或戒断，并诱导麻醉，以及增强认知能力。
• Modified Malonate Derivatives
  申请人：Grimm Jonathan

  公开号：US20100160327A1

  公开（公告）日：2010-06-24

  The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.

  本发明涉及一种新的改性丙二酸酯衍生物类，这些改性丙二酸酯化合物可用于治疗癌症。这些改性丙二酸酯化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导终末分化，阻止肿瘤细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤细胞增殖特征的患者方面非常有用。本发明的化合物还可以用于预防和治疗TRX介导的疾病，例如自身免疫、过敏和炎症性疾病，并用于预防和/或治疗中枢神经系统（CNS）疾病，例如神经退行性疾病。本发明还提供了包括改性丙二酸酯衍生物的药物组合物和这些药物组合物的安全用药方案，这些方案易于遵循，并在体内产生治疗有效量的改性丙二酸酯衍生物。
• INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：CATENA RUIZ Juan Lorenzo

  公开号：US20130303522A1

  公开（公告）日：2013-11-14

  The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

  公式（I）的化合物是由过氢化喹啉和过氢化异喹啉衍生而来的，可用作活性药物成分，用于预防或治疗由11-beta-羟基类固醇脱氢酶类型1（11-beta-HSD1）酶相关疾病引起的疾病，如青光眼、眼压升高、代谢紊乱、肥胖症、代谢综合征、血脂异常、高血压、糖尿病、动脉硬化、库欣综合征、银屑病、类风湿性关节炎、认知障碍、阿尔茨海默病或神经退行性疾病。
• Pharmaceutically useful malonamides
  申请人：Research Corporation

  公开号：EP0135189A2

  公开（公告）日：1985-03-27

  Compounds of the formula wherein R, and R2 are the same or different and are hydrogen or alkyl with the proviso that R1 are R2 are not both hydrogen, R1 and R2 are preferably hydrogen or a lower alkyl of 1 to 8 carbon atoms, a pharmaceutical composition comprising an anti-epileptic effective amount of the above described compound, and a method of treating epilepsy comprising administering to a mammal an anti-epileptic amount of the above-described pharmaceutical composition.

  式中的化合物 其中 R 和 R2 相同或不同，并且是氢或烷基，但 R1 和 R2 不能都是氢，R1 和 R2 最好是氢或 1 至 8 个碳原子的低级烷基，一种药物组合物，包含抗癫痫有效量的上述化合物，以及一种治疗癫痫的方法，包括给哺乳动物服用抗癫痫有效量的上述药物组合物。
• S-substituted beta-thioacrylamides and their use as microbicides
  申请人：ROHM AND HAAS COMPANY

  公开号：EP0410726A1

  公开（公告）日：1991-01-30

  S-substituted beta-thioacrylamide compounds have been discovered to be useful as microbicides, particularly fungicides. Compositions comprising said compounds and isothiazolin-3-ones and/or carriers, methods of preparation of the compounds and methods of using the compounds and compositions are also disclosed.

  已发现 S-取代β-硫代丙烯酰胺化合物可用作杀微生物剂，特别是杀真菌剂。此外，还公开了包含上述化合物和异噻唑啉-3-酮和/或载体的组合物、化合物的制备方法以及化合物和组合物的使用方法。